status: 200
content-location: http://rest.kegg.jp/get/path:map05218
server: Apache
date: Wed, 15 Oct 2014 14:59:10 GMT
content-type: text/plain

ENTRY       map05218                    Pathway
NAME        Melanoma
DESCRIPTION Melanoma is a form of skin cancer that has a poor prognosis and which is on the rise in Western populations.  Melanoma arises from the malignant transformation of pigment-producing cells, melanocytes. The only known environmental risk factor is exposure to ultraviolet (UV) light and in people with fair skin the risk is greatly increased. Melanoma pathogenesis is also driven by genetic factors. Oncogenic NRAS mutations activate both effector pathways Raf-MEK-ERK and PI3K-Akt. The Raf-MEK-ERK pathway may also be activated via mutations in the BRAF gene. The PI3K-Akt pathway may be activated through loss or mutation of the inhibitory tumor suppressor gene PTEN. These mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Melanoma development has been shown to be strongly associated with inactivation of the p16INK4a/cyclin dependent kinases 4 and 6/retinoblastoma protein (p16INK4a/CDK4,6/pRb) and p14ARF/human double minute 2/p53 (p14ARF/HMD2/p53) tumor suppressor pathways. MITF and TP53 are implicated in further melanoma progression.
CLASS       Human Diseases; Cancers
PATHWAY_MAP map05218  Melanoma
DISEASE     H00038  Malignant melanoma
REFERENCE   PMID:16822996
  AUTHORS   Miller AJ, Mihm MC Jr.
  TITLE     Melanoma.
  JOURNAL   N Engl J Med 355:51-65 (2006)
REFERENCE   PMID:12894244
  AUTHORS   Chin L.
  TITLE     The genetics of malignant melanoma: lessons from mouse and man.
  JOURNAL   Nat Rev Cancer 3:559-70 (2003)
REFERENCE   PMID:16750612
  AUTHORS   Takata M, Saida T.
  TITLE     Genetic alterations in melanocytic tumors.
  JOURNAL   J Dermatol Sci 43:1-10 (2006)
REFERENCE   PMID:15841168
  AUTHORS   Chudnovsky Y, Khavari PA, Adams AE.
  TITLE     Melanoma genetics and the development of rational therapeutics.
  JOURNAL   J Clin Invest 115:813-24 (2005)
REFERENCE   PMID:16001050
  AUTHORS   Merlino G.
  TITLE     Cancer biology: the weakest link?
  JOURNAL   Nature 436:33-5 (2005)
REFERENCE   PMID:16001072
  AUTHORS   Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR.
  TITLE     Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
  JOURNAL   Nature 436:117-22 (2005)
REFERENCE   PMID:16899407
  AUTHORS   Levy C, Khaled M, Fisher DE.
  TITLE     MITF: master regulator of melanocyte development and melanoma oncogene.
  JOURNAL   Trends Mol Med 12:406-14 (2006)
REFERENCE   PMID:15009714
  AUTHORS   Tsao H, Goel V, Wu H, Yang G, Haluska FG.
  TITLE     Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
  JOURNAL   J Invest Dermatol 122:337-41 (2004)
REFERENCE   PMID:11224709
  AUTHORS   Gruss C, Herlyn M.
  TITLE     Role of cadherins and matrixins in melanoma.
  JOURNAL   Curr Opin Oncol 13:117-23 (2001)
REFERENCE   PMID:15721476
  AUTHORS   Thompson JF, Scolyer RA, Kefford RF.
  TITLE     Cutaneous melanoma.
  JOURNAL   Lancet 365:687-701 (2005)
REFERENCE   PMID:14695152
  AUTHORS   Omholt K, Platz A, Kanter L, Ringborg U, Hansson J.
  TITLE     NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
  JOURNAL   Clin Cancer Res 9:6483-8 (2003)
REFERENCE   PMID:15557758
  AUTHORS   Hussein MR.
  TITLE     The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship?
  JOURNAL   Tumour Biol 25:200-7 (2004)
REFERENCE   PMID:10843728
  AUTHORS   Lazar-Molnar E, Hegyesi H, Toth S, Falus A.
  TITLE     Autocrine and paracrine regulation by cytokines and growth factors in melanoma.
  JOURNAL   Cytokine 12:547-54 (2000)
KO_PATHWAY  ko05218
///
